WO2016182277A2 - Procédé d'administration transdermique pour substance bioactive employant un nanodiamant - Google Patents

Procédé d'administration transdermique pour substance bioactive employant un nanodiamant Download PDF

Info

Publication number
WO2016182277A2
WO2016182277A2 PCT/KR2016/004784 KR2016004784W WO2016182277A2 WO 2016182277 A2 WO2016182277 A2 WO 2016182277A2 KR 2016004784 W KR2016004784 W KR 2016004784W WO 2016182277 A2 WO2016182277 A2 WO 2016182277A2
Authority
WO
WIPO (PCT)
Prior art keywords
skin
bioactive
substance
hydrophobic
hydrophilic
Prior art date
Application number
PCT/KR2016/004784
Other languages
English (en)
Korean (ko)
Other versions
WO2016182277A3 (fr
Inventor
권명택
리치제레미
김선옥
임선희
지정대
Original Assignee
나노리소스 주식회사
주식회사 에스티에스네트웍스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 나노리소스 주식회사, 주식회사 에스티에스네트웍스 filed Critical 나노리소스 주식회사
Publication of WO2016182277A2 publication Critical patent/WO2016182277A2/fr
Publication of WO2016182277A3 publication Critical patent/WO2016182277A3/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/06—Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles

Definitions

  • the present invention relates to a method for transdermal delivery of a physiologically active substance using nanodiamonds, and simultaneously attaches and solubilizes a hydrophilic physiologically active substance and a hydrophobic physiologically active substance to the surface of the nanodiamond, and then applies the physiologically active substance to the skin surface. It is about how to deliver.
  • the skin is histologically composed of epidermis, dermis, subcutaneous fat and the like, and its thickness varies according to the site, age and sex. Although various skin conditions exist, these skins each play a role of external barrier function and other physiological functions.
  • the stratum corneum is a layer of keratinized dead cells with relatively high density of hydrophobicity insoluble protein keratin, interposed between an intercellular lipid bilayer, a thin layer of lipids.
  • the unique hierarchical structure of the matrix rich in lipids and insoluble proteins, makes it impermeable to chemical factors, including various compounds from external environments.
  • the hydrophilic bioactive material is very difficult to permeate due to this hydrophobic multiple structure of the stratum corneum.
  • the transport of substances through keratin, especially the hydrophilic bioactive substances in healthy skin is not easily achieved due to various protective actions of the skin, and only a very low concentration is transmitted even if permeated.
  • the physiologically active substances contained in the cosmetics must pass through the stratum corneum, the outermost layer of the skin in order to show its efficacy, and in the case of hydrophilic bioactive substances, due to the hydrophobic multiple structure of the stratum corneum and its barrier function, Bioactive substances contained in have a problem that does not sufficiently exhibit its function.
  • Skin penetration routes of bioactive molecules through the skin are generally divided into three types: stratum corneum, hair follicle and sebaceous gland, sweat gland.
  • stratum corneum stratum corneum
  • hair follicle hair follicle and sebaceous gland
  • sweat gland sweat gland
  • the direct transcellular pathway to the stratum corneum as a skin barrier is not easy and the intercellular pathway through the intercellular lipid layer is known to be relatively efficient. It uses the intercellular lipid layer pathway composed of nonpolar lipids. Polar materials can hardly penetrate the intercellular lipid layer, but hydrophobic materials are easy to permeate.
  • the system used for the transdermal delivery of physiologically active substances contained in cosmetics is mainly to make and apply vesicles containing the active substance to materials such as surfactants, lipids, polymers, etc.
  • the lipid component is a component of the biological membrane As it can promote transdermal penetration through the improvement of skin affinity and skin absorption of physiologically active substances, it is preferentially utilized over other materials.
  • liposomes which are the most widely used vesicles in cosmetic formulations, are structures consisting of a single layer or multiple layers of lipid bilayers that are most similar to biological membranes. It is used as one of the transdermal delivery systems that facilitates skin delivery of active molecules.
  • the physicochemical instability of the membrane itself, low emulsification stability among other things, the efficiency of the drug collection and maintenance of the stability of the drug itself is very low and the penetration rate of the skin is also poor, and as a result, the efficacy is very limited.
  • the carrier supporting liposome-containing bioactive molecules and improving the skin permeation should be able to maintain the stability of the carrier itself and the stabilization of the support material as much as possible, and the composition, particle size, surface charge of the particles, zeta potential It is necessary to optimize the characteristics of the carrier, such as size and pH, and ultimately, when applying skin, it is necessary to secure safety and improve efficacy by bioactive molecules.
  • Some dermal penetration promoters are known to act on desmosomes and related proteins involved in intercellular binding of keratinocytes, thereby facilitating delivery through mechanisms that separate or loosen keratinocyte intercellular bonds and increase intercellular spacing.
  • Other skin penetration promoters are known to facilitate delivery through mechanisms that penetrate inside keratinocytes to denature keratin or affect internal structure, facilitating delivery through the transcellular route.
  • Skin permeation accelerators inevitably alter the structure of the stratum corneum, which is the outermost skin layer, to promote skin permeation of bioactive substances.
  • stratum corneum which is the outermost skin layer
  • most skin permeation accelerators have high cytotoxicity to skin cells and have a very high possibility of causing skin irritation such as causing skin burning and erythema upon application.
  • the production of nanodiamonds by explosion reaction is carried out in a closed metal chamber under a gas atmosphere, for example, carbon dioxide (CO2) or water (H2O) or other liquid reducing agent conditions. Obtained by explosion reaction with, 4,6-trinitrotoluene (TNT) / 1,3,5-trinitrotriazacyclohexane (also known as hexogen or RDX).
  • a gas atmosphere for example, carbon dioxide (CO2) or water (H2O) or other liquid reducing agent conditions.
  • CO2 carbon dioxide
  • H2O water
  • TNT 4,6-trinitrotoluene
  • TNT 1,3,5-trinitrotriazacyclohexane
  • DND occurs instantaneously when an explosive substance reacts with a mixture of explosive trinitrotoluene (TNT) and white crystalline non-aqueous explosive (RDX), at a certain ratio, for example, in the tens percent by weight.
  • TNT explosive trinitrotoluene
  • RDX white crystalline non-aqueous explosive
  • the carbon component of the composition generates nuclei of diamond crystal phase (carbon sp 3 structure), and the nucleus grows to a certain size, and on the graphite (sp 2 structure) surface, C, O, H, N And a plurality of functional groups.
  • Representative functional groups thereof are known to have a large number of COOH, C ⁇ O, NH 2 , CHO, OH, NO 2 , -COC- and the like.
  • DND has little toxicity in vivo and is biocompatible due to the stability of the structure, and has a very small particle size of several nm size and specific surface area of 250 m 2 / g-450 m 2 / g. It is about ten to hundred times larger than diamond and its unique electrical, chemical and optical properties, including its many hydrophilic functional groups, can be used in a wide range of industries.
  • the present invention provides a method for delivering a bioactive substance into the skin without skin irritation or toxicity.
  • the present invention provides a method for easily penetrating into the skin a hydrophilic bioactive material that is difficult to deliver into the skin.
  • a solubilization step of mixing a hydrophobic skin bioactive substance, a hydrophilic skin bioactive substance and nanodiamonds in a solvent comprising applying the solubilized solution to the skin.
  • the present invention is a solubilization step of mixing hydrophobic skin bioactive material, hydrophilic skin bioactive material and nanodiamond in a solvent, separating and drying the nanodiamond complex from the solubilized solution and the nanodiamond complex It relates to a method of transdermal delivery of a bioactive material comprising the step of dispersing in a solution and applying to the skin.
  • the method of the present invention can carry a hydrophilic bioactive material at the same time as the solubilization of the hydrophobic bioactive material, so that the hydrophilic bioactive material, which is difficult to penetrate the stratum corneum, is delivered to the skin together with the hydrophobic material to improve skin permeability.
  • the method of the present invention can deliver a bioactive substance into the skin without skin irritation or toxicity.
  • the method of the present invention can improve the skin permeability of the hydrophilic active material that is difficult to penetrate the skin using the nanodiamond complex, and at the same time the nanodiamond itself remains on the skin surface to improve the dryness of the skin through a moisturizing effect.
  • the present invention can support a significant amount of bioactive materials at a molecular level corresponding to the functional groups of the nanodiamond surface, thereby providing the effects of skin bioactive materials over a long period of time.
  • the present invention is also applied to cosmetic compositions such as skins, lotions, essences, creams, packs for the purpose of antioxidant efficacy, wrinkle reduction, melanin reduction, skin irritation, skin UV protection, skin dryness prevention, hair loss prevention, etc. can do.
  • FIG. 2 is a schematic diagram showing that the hydrophobic bioactive material is bound to the nanodiamond surface functional group by the solubilization step, and b of FIG. 2 is a hydrophilic bioactive material (vitamin C) and a hydrophobic bioactive material (eugenol). It is a schematic diagram showing that they are combined randomly (in any order or order).
  • FIG. 6 is FT-IR of ND-Eugenol-vitamin C prepared in Example 2.
  • FIG. 7 is an FT-IR image of ND-Glutathione-Hesperidine-Eugenol prepared in Example 3.
  • Figure 8 is a skin permeation experiment of Experiment 1 was taken with a confocal microscope.
  • the present invention relates to a method of solubilizing hydrophobic and hydrophilic bioactive materials and delivering them to the skin using nanodiamonds.
  • the method of transdermal delivery of a bioactive material of the present invention includes a solubilization step and a skin application step.
  • the solubilization step includes mixing hydrophobic skin bioactive material, hydrophilic skin bioactive material and nanodiamond in a solvent.
  • FIG. 1 illustrates the surface structure of explosive nanodiamonds.
  • 2 is a schematic diagram showing that the hydrophobic bioactive material is bound to the nanodiamond surface functional group by the solubilization step, and b of FIG. 2 is a hydrophilic bioactive material (vitamin C) and a hydrophobic bioactive material (eugenol). It is a schematic diagram showing that they are combined randomly (in any order or order).
  • the explosive nanodiamonds have functional groups such as COOH, C ⁇ O, NH 2 , CHO, OH, NO 2 , and —COC—.
  • the surface functional groups of the nanodiamonds may be surface modified with any one or more of Carboxyl, Lactone, Hydroxy, Phenol, Thiol, and Amine.
  • the average size of one nanodiamond particle may be 10 nm or more and 100 nm or less, and the number of functional groups attached to one particle may be 10,000 or more and 1,000,000 or less.
  • the nanodiamond can be combined with a very large amount of bioactive material.
  • a linker may be attached to the nanodiamond surface functional group to amplify the number of functional groups.
  • the linker alkylamine, arylamine, sugar, antioxidant, protein, peptide, nucleic acid or SiCH compound may be used.
  • the linker may be covalently bonded to a functional group.
  • the physiologically active substance can use any known substance that affects skin improvement without limitation.
  • the skin bioactive material may include an organic material, an inorganic material, or both thereof.
  • an organic material such as an inorganic material, or both thereof.
  • an inorganic material such as an inorganic material, or both thereof.
  • To the functional group (10,000 to 1,000,000 pieces) of the surface of the nanodiamond, different kinds of bioactive substances at the molecular level may be attached.
  • the organic material may be vitamins, lipids, proteins, peptides, flavonoids, nucleic acids, natural substance groups.
  • the inorganic material may include carbon silicon-based, carbon sulfide-based, and carbon phosphide-based compounds in which Si, S, and P are bonded to carbon.
  • the skin bioactive substance is eugenol, ascorbic acid, vitamin A, vitamin B, vitamin C, vitamin E, vitamin K, vitamin P, hydroquinone, hesperidin, glutathione, EGCG, retinol, adenosine, hyaluronic acid Lonic acid, tannic acid, peptides, polyphenols, flavonoids and derivatives thereof.
  • the molecular weight of the bioactive material may be 2 to 500,000 or less, preferably 2 to 500 or less.
  • the hydrophilic bioactive substance refers to a hydrophilic substance and an excellent skin improving effect, and is not particularly limited as long as it is known to those skilled in the art, for example, arbutin, adenosine, vitamin C and Hydrophilic derivatives thereof, vitamin B3, vitamin B5, vitamin H and other hydrophilic vitamins and derivatives thereof, centella asiatica extract including acetylglucosamine, madecassoside, selenium aspartate, various plant extracts and various peptide components or It may be a mixture of two or more components.
  • Hydrophobic physiologically active substances are predominantly hydrophobic properties, such as eugenol, Retinol, ASTAXANTHIN, CAFFEIC ACID, CARNOSIC ACID, CATECHIN, COENZYME-Q10, CURCUMIN, ELLAGIC ACID, FERULIC ACID, IDEBENONE, ISOFLAVONE, LINOLEIC ACID, LIPOC , OLEANOLIC ACID, PHLORETIN, QUERCETIN, RESVERATROL, SQUALANE, SQUALENE, TANNIC ACID, VITAMIN A, VITAMIN B VITAMIN E, VITAMIN F, CHOLESTEROL, PHYTOSPHINGOSINE, SQUALENE, GLYCOSPHINGOLIPIO
  • the hydrophobic bioactive material is a material that is easy to penetrate the stratum corneum based on the partition coefficient, and the hydrophilic bioactive material is permeable to the stratum corneum Can be a difficult substance.
  • the hydrophobic bioactive material has a distribution coefficient (log P value) of 1 to 3, and is easy to penetrate the stratum corneum, and the hydrophilic bioactive material is difficult to penetrate the skin stratum corneum (distribution coefficient (log P value). ) May be less than 1).
  • the hydrophobic skin bioactive material or hydrophilic skin bioactive material may be used to have antioxidant, anti-wrinkle, whitening, moisturizing or hair loss prevention activity.
  • the bioactive substance having the antiwrinkle activity may be selected from the group of skin cell growth factors, proteins or peptides, retinol, retinyl palmitate, adenosine and polyethoxylatedretinamide.
  • the bioactive substance having the whitening activity may be selected from arbutin, ascorbic acid, acetyl ascorbyl ether, ascorbyl glucoside, niacinamide, ascorbyl phosphate, bisabolol, whitening peptide group.
  • the solvent may be water, ethanol or a mixture of water and ethanol, or buffer solutions.
  • the solubilization step may control the pH according to the concentration or hydrophobicity, nanodiamond content of the hydrophobic skin bioactive material and the hydrophilic skin bioactive material.
  • the solubilization step may be a pH of 3 to 10, preferably 5 to 8, more preferably 6 to 7.
  • the solubilization step may stir the solution strongly for a predetermined time.
  • the mixing time may be 24 hours.
  • the mixed solution may be mixed (strongly) using ultrasonic waves.
  • the solubilization step of the present invention can be carried out by stirring the mixture at an appropriate pH condition without additives such as surfactants.
  • hydrophilic bioactive material hydrophobic bioactive material may be mixed in an appropriate range.
  • the method may add more than 2000ppm of the nanodiamond. More specifically, the nanodiamonds may be added in an amount of 0.001 to 20 wt% based on the solvent.
  • the content of the bioactive material may be 5-30% of the weight of the surface-modified nanodiamond.
  • the content of the bioactive substance may be in the range of 0.1 to 1,000% of the weight of the surface-modified nanodiamond.
  • the hydrophilic bioactive material and the hydrophobic bioactive material are uniformly present in the solvent through non-covalent bonding with nanodiamonds.
  • the solubilization step is a step in which the hydrophobic skin bioactive material and the hydrophilic skin bioactive material are non-covalently bonded to the surface functional group of the nanodiamond at the same time.
  • the non-covalent bond between the nanodiamond and the physiologically active substance may be a hydrogen bond, an electrostatic bond, or a van der Waals bond.
  • solubilization used in the present invention is used as a term indicating a state in which a hydrophilic bioactive substance and a hydrophobic bioactive substance which are not dissolved in each other are uniformly mixed with a hydrophilic or hydrophobic solvent.
  • physiologically active substance in the case of an inorganic substance
  • it is represented as "solubilization”. Nanodiamonds of the present invention are not dissolved but dispersed in a solvent even after a solubilization step.
  • the present inventors have come to the present invention knowing that solubilization of hydrophilic and hydrophobic physiologically active substances that do not dissolve with each other is due to nanodiamonds.
  • the inventors have determined that the bioactive materials are solubilized by the interaction between the bioactive material and the functional group present on the surface of the nanodiamond and the nanodiamond surface moisture layer.
  • the hydrophobic and hydrophilic bioactive materials may be present in a molecular unit by 10,000 or more and 1,000,000 or less functional groups present on the surface of the nanodiamond particles.
  • 2B is a conceptual diagram showing that molecules of hydrophobic and hydrophilic bioactive materials are randomly bonded to the nanodiamond surface functional group randomly (in any order or order) by the mixing step.
  • hydrophobic bioactive material 20 is bonded to some of these functional groups, hydrophilic bioactive material to be coupled to the other part Can be. That is, a large number of hydrophilic bioactive molecules and hydrophobic bioactive molecules may be simultaneously supported on one nanodiamond particle.
  • the molar range of the physiologically active substance bound per nanodiamond particle may be in the range of 1 ⁇ 10 ⁇ 4 mol / g ⁇ 1 ⁇ 10 ⁇ 2 mol / g.
  • the present inventors maintain that the nanodiamond particles are stably combined with hundreds of thousands to hundreds of thousands of hydrophobic bioactive molecules and hydrophilic bioactive molecules at the same time, with 10,000 to 1,000,000 or less present on the surface of the nanodiamond. It is understood because of the functional groups and the activation energy of these functional groups.
  • FIG. 3 is a mixture of a hydrophobic bioactive substance Eugenol and a hydrophilic bioactive substance vitamin C in water without using nanodiamonds
  • FIG. 4 is a solution in which nanodiamonds are added and mixed.
  • the solubilization method of the present invention can be stably supported on nanodiamonds without the molecular structure or active modification of the bioactive material.
  • the present invention can add a cosmetic to the solubilized solution to prepare a cosmetic composition.
  • the cosmetic may be a flexible lotion (skin), nourishing lotion (milk lotion), nourishing cream, massage cream or essence.
  • the cosmetic may include a whitening agent, a moisturizing agent, an antioxidant, an ultraviolet absorber, a surfactant, a thickener, an alcohol, a preservative, a gelling agent, a fragrance, a filler, or a dye.
  • the method may prepare the solubilized solution or cosmetic composition in the form of a gel or an emulsion.
  • the method may be prepared in powder form by drying the solubilized solution.
  • the present invention includes applying the solubilized solution or the cosmetic composition to the skin.
  • the skin coating step includes the step of releasing a hydrophilic bioactive material and a hydrophobic bioactive material which are non-covalently bound to the surface of the nanodiamond, and the hydrophilic organic material and the hydrophobic organic material together into the skin through each skin epidermal gap. Infiltration may be included.
  • the hydrophilic bioactive material and the hydrophobic bioactive material non-covalently bound to the functional group of the nanodiamond can be separated from the functional group by the pH change of the skin and penetrate into the skin.
  • the release step may be separated from the functional group by the concentration difference between the hydrophilic bioactive material and the hydrophobic bioactive material non-covalently bonded to the functional group of the nanodiamond to penetrate into the skin.
  • the hydrophilic bioactive material and hydrophobic bioactive material may be separated from the nanodiamond by the concentration of salts contained in body fluids such as sweat or body fluids, and may penetrate into the skin.
  • the skin bioactive material penetrates into the skin, but the nanodiamond remains on the surface of the skin as it is.
  • Example 2 2 g of the nanodiamond prepared in Example 1 was added to 900 mL of deionized water, dispersed for 60 minutes using ultrasonic waves, and then allowed to stand at room temperature. After titrating the pH to 7, using 0.25N NaOH solution, 100 mg of hydrophilic bioactive substance Vitamin C and 100 mg of hydrophobic bioactive substance Eugenol were added thereto, stirred for 10 minutes, and deionized water was added to 1000 mL. The solid and the liquid were separated by centrifugation at 10,000 rpm for 10 minutes and washed once to prepare ND-Eugenol-vitamin C in powder form.
  • the prepared ND- Eugenol-vitamin C was confirmed the presence or absence of the active material of the complex using FT-IR (Fig. 6).
  • Example 2 2 g of the nanodiamond prepared in Example 1 was added to 900 mL of deionized water, dispersed for 60 minutes using ultrasonic waves, and then allowed to stand at room temperature. After titrating the pH to 7, using 0.25N NaOH solution, add 2mg of hydrophilic bioactive substance Glutathione, 0.2mg of hydrophobic bioactive substance, 0.2mg of Eugenol and 100mg of Eugenol for 10 minutes, and then deionized water to 1000mL. Was added. The solid and the liquid were separated by centrifugation at 10,000 rpm for 10 minutes and washed once to prepare ND-Glutathione-Hesperidine-Eugenol in powder form.
  • the prepared ND-Glutathione-Hesperidine-Eugenol was confirmed the presence or absence of the active material of the complex using FT-IR (Fig. 7).
  • ND-COOH 1g SOCl 2 The mixture was added to a mixture of 30 mL and 0.15 mL of anhydrous DMF, and then completely dispersed using ultrasonic waves. After the mixed solution was warmed at 70 ° C. for 24 hours, the remaining SOCl 2 was removed by distillation under low temperature and reduced pressure.
  • the ND-COCl 2 obtained in the reaction was completely mixed with anhydrous DMSO using ultrasonic waves, and 0.3 mL of pyridine and 5 g of ethylenediamine were added thereto. The mixture was stirred for 24 hours at room temperature to react, and after removing DMSO using a vacuum apparatus, the reaction mixture was washed by centrifugation (10,000 rpm, 10 minutes) with deionized water and the process was repeated five times.
  • the soluble solution prepared above was applied to the skin about 0.5 mL.
  • Example 1 the hydrophobic bioactive substance Eugenol and the hydrophilic bioactive substance vitamin C were added to water and stirred without adding nanodiamonds (content conditions are the same as those in Example 1).
  • the receptor was filled with PBS solution (phosphate-buffered saline, pH 7.4, 32 ° C) and allowed to stand for 1 hour so that the pig skin was in equilibrium with the PBS solution. Thereafter, the ND-COOH fluorescent derivative prepared in Example 4 was dispersed in 0.5 mL of water and applied to the skin. After 12, 24 and 48 hours, the skin tissue was recovered, washed with deionized water, and then fixed in 10% Formaldehyde for 18 hours. After fixation, cryosections (14 ⁇ m) were prepared using a Microm HM520 cryostat, Thermo, and placed on a glass slide.
  • PBS solution phosphate-buffered saline, pH 7.4, 32 ° C
  • the prepared slides were stained with PBS buffer for 10 minutes and stained with cell nuclei in tissues by exposure to 0.2 mM DAPI solution for 7 minutes.
  • the stained tissue was washed again with PBS buffer three times for 10 minutes, and then fixed on a slide using a mounting medium, and observed with a confocal microscope. The results are shown in FIG. 8.
  • the fluorescent control which is a negative control group, penetrated the skin, but the fluorescence bound to ND did not penetrate the skin.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Birds (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Dermatology (AREA)
  • General Life Sciences & Earth Sciences (AREA)
  • Geology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne un procédé pour administrer une substance bioactive dans la peau en fixant et en solubilisant simultanément une substance bioactive hydrophile et une substance bioactive hydrophobe sur une surface de nanodiamant, puis en en recouvrant une surface de la peau. Le procédé de la présente invention permet la solubilisation de la substance bioactive hydrophobe et le chargement de la substance bioactive hydrophobe avec la substance bioactive hydrophile en même temps, de sorte que la substance bioactive hydrophile, qu'il est difficile de faire pénétrer dans la couche cornée de la peau, conjointement à la substance hydrophobe, est administrée dans la peau, en améliorant ainsi sa pénétration de la peau. Dans le procédé de la présente invention, la substance bioactive peut être administrée dans la peau sans irritation de la peau ni toxicité. Dans le procédé de la présente invention, la pénétration dans la peau de la substance active hydrophile, qu'il est difficile de faire pénétrer dans la peau, peut être améliorée par l'utilisation d'un composite de nanodiamant, et, en même temps, le nanodiamant lui-même reste sur la surface de la peau pour atténuer la sécheresse de la peau grâce à un effet hydratant.<i />
PCT/KR2016/004784 2015-05-08 2016-05-09 Procédé d'administration transdermique pour substance bioactive employant un nanodiamant WO2016182277A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2015-0064876 2015-05-08
KR1020150064876A KR101876282B1 (ko) 2015-05-08 2015-05-08 나노다이아몬드를 이용한 생리 활성물질의 경피 전달용 조성물 및 이의 제조방법

Publications (2)

Publication Number Publication Date
WO2016182277A2 true WO2016182277A2 (fr) 2016-11-17
WO2016182277A3 WO2016182277A3 (fr) 2017-01-12

Family

ID=57249602

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2016/004784 WO2016182277A2 (fr) 2015-05-08 2016-05-09 Procédé d'administration transdermique pour substance bioactive employant un nanodiamant

Country Status (2)

Country Link
KR (1) KR101876282B1 (fr)
WO (1) WO2016182277A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019242705A1 (fr) * 2018-06-22 2019-12-26 Master Dynamic Limited Composition d'hydratation de la peau

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101875407B1 (ko) * 2017-09-22 2018-07-06 나노다이아랩(주) 아스타잔틴이 분산된 화장료 조성물의 제조방법
KR102142960B1 (ko) * 2018-08-17 2020-08-10 이강현 마유 및 나노다이아몬드를 이용한 나노리포좀 제조방법 및 이의 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100305309A1 (en) * 2009-05-28 2010-12-02 Northwestern University Nanodiamond particle complexes
TWI414309B (zh) * 2009-07-13 2013-11-11 Univ Nat Chiao Tung 包括奈米鑽石的載體、藥物及其製備的方法和用途

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019242705A1 (fr) * 2018-06-22 2019-12-26 Master Dynamic Limited Composition d'hydratation de la peau

Also Published As

Publication number Publication date
KR20160132296A (ko) 2016-11-17
WO2016182277A3 (fr) 2017-01-12
KR101876282B1 (ko) 2018-07-10

Similar Documents

Publication Publication Date Title
JP5128592B2 (ja) 皮膚外用剤に有用なベシクル及び該ベシクルを含有する皮膚外用剤
WO2016182277A2 (fr) Procédé d&#39;administration transdermique pour substance bioactive employant un nanodiamant
KR20100100875A (ko) 스테롤-개질된 양친매성 지질
Song et al. Daidzein-loaded nanostructured lipid carriers-PLGA nanofibers for transdermal delivery
KR20150092102A (ko) 적어도 하나의 하이드로트로프 및 적어도 하나의 활성제을 포함하는 화장용 조성물
WO2019059661A1 (fr) Procédé de préparation d&#39;une composition cosmétique comportant une substance biologiquement active dispersée dans celle-ci
KR100949848B1 (ko) 비타민ｃ 유도체 함유 나노유화 화장료 조성물 및 그의제조방법
JP4228230B2 (ja) リポソーム懸濁液の製造方法及びリポソームを用いた用途
WO2021054773A1 (fr) Composition cosmétique ayant une formulation d&#39;émulsions multiples pour la stabilisation d&#39;ingrédient actif et l&#39;accélération de l&#39;absorption cutanée
KR20160132295A (ko) 생리활성물질-나노다이아몬드 복합체 및 이를 포함하는 조성물
CN109700671A (zh) 包含活性小分子物质的柔性脂质体化妆品及其制备方法
WO2016108634A2 (fr) Nanostructure multi-lamellaire de type hybride de facteur de croissance épidermique et liposome et procédé de fabrication associé
EP1592452B1 (fr) Composition de type emulsion inverse contenant au moins un agent actif sensible a la presence d&#39;eau, et son utilisation dans le domaine cosmetique et en dermatologie
Hardiningtyas et al. Mechanistic investigation of transcutaneous protein delivery using solid-in-oil nanodispersion: A case study with phycocyanin
KR20110037863A (ko) 옥사졸리딘-2-온 화합물을 캡슐화한 리포좀
WO2018230788A1 (fr) Composition pour l&#39;administration d&#39;un médicament par voie orale contenant de l&#39;oxaliplatine et son procédé de préparation
CN115298190A (zh) 离子液体、溶剂、制剂及经皮吸收剂
CN112043670B (zh) 一种线粒体靶向型外用药物制剂
WO2020085857A1 (fr) Système d&#39;administration transdermique comprenant une micelle inverse
KR102509693B1 (ko) 이데베논을 포함하는 항산화 및 피부 보습용 화장료 조성물
EP3643300A2 (fr) Complexe chitosan-pluronic et nanosupport le comprenant
EP1647277A1 (fr) Liposome contenant du glycoside
Arafat The effect of intestinal bile on the stability of lipid-based vesicular system used as oral drug carriers
JP5913105B2 (ja) 両親媒性酸分子による塩基性活性成分の協同輸送
WO2018004068A1 (fr) Composition visant à stimuler la sécrétion de sébum

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16792923

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16792923

Country of ref document: EP

Kind code of ref document: A2